NeoGenomics, Inc.: RaDaR Assay Demonstrates Clinical Potential for Detecting Disease Recurrence Across All Types of Early Breast Cancer, Including Triple Negative Disease
Data presented at this year's San Antonio Breast Cancer Symposium builds on strong base of evidence supporting promise of RaDaR in helping prevent recurrence and improving outcomesFT. MYERS, FL / ACCESSWIRE